Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.
The lack of proven screening tools for early detection and the high mortality of ovarian serous carcinoma (OSC), particularly high grade, have focused attention on identifying putative precursor lesions with distinct morphological and molecular characteristics. The finding of occult invasive and intraepithelial fallopian tube carcinomas in prophylactically removed specimens from asymptomatic high-risk BRCA 1/2-mutation carriers supports the notion of an origin for OSC in the fallopian tube. The intraepithelial carcinomas have been referred to as serous intraepithelial carcinomas (STICs) but our own findings (unpublished data) and recent reports have drawn attention to a spectrum of changes that fall short of STICs that we have designated serous tubal intraepithelial lesions (STILs).
Gross
Amy L
AL
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Kurman
Robert J
RJ
Vang
Russell
R
Shih
Ie-Ming
IeM
Visvanathan
Kala
K
Am J Pathol. 2004 May;164(5):1511-8
15111296
Am J Surg Pathol. 2007 Feb;31(2):161-9
17255760
Clin Cancer Res. 2008 Jul 1;14(13):4067-78
18593983
Cell Res. 2009 Jan;19(1):47-57
19114989
Methods Mol Biol. 2009;472:413-37
19107446
Int J Gynecol Pathol. 2002 Oct;21(4):407-11
12352190
J Pathol. 2007 Jan;211(1):26-35
17117391
J Natl Cancer Inst. 2002 Jan 2;94(1):32-8
11773280
Gynecol Oncol. 2006 Nov;103(2):719-28
16698071
Gynecol Oncol. 1983 Feb;15(1):10-7
6822361
Am J Hum Genet. 1995 Jan;56(1):265-71
7825587
J Natl Cancer Inst. 1997 Jul 2;89(13):932-8
9214672
Lancet. 2007 May 19;369(9574):1703-10
17512855
Hum Pathol. 1995 Nov;26(11):1268-74
7590703
Am J Pathol. 2006 Jul;169(1):258-67
16816378
Lancet. 1994 Mar 19;343(8899):692-5
7907678
JAMA. 2006 Jul 12;296(2):185-92
16835424
N Engl J Med. 2002 May 23;346(21):1616-22
12023993
Gynecol Oncol. 2006 Jan;100(1):58-64
16137750
Am J Epidemiol. 1983 Feb;117(2):128-39
6681935
Am J Obstet Gynecol. 2006 Jun;194(6):1702-9
16731090
Am J Surg Pathol. 2006 Feb;30(2):230-6
16434898
Int J Cancer. 2006 Sep 15;119(6):1412-8
16615107
Lancet Oncol. 2008 Dec;9(12):1191-7
19038766
Gynecol Oncol. 2002 Oct;87(1):52-6
12468342
Gynecol Oncol. 2008 Nov;111(2):226-32
18718648
Br J Cancer. 2004 Apr 19;90(8):1492-7
15083174
Hum Pathol. 1995 Nov;26(11):1260-7
7590702
Oncology (Williston Park). 1998 Jun;12(6):813-9; discussion 820, 825-6
9644683
Gynecol Oncol. 2005 May;97(2):476-82
15863147
Hum Pathol. 1999 Feb;30(2):151-7
10029442
Cancer. 2000 Jul 15;89(2):383-90
10918170
Am J Pathol. 1997 Jan;150(1):177-85
9006334
Gynecol Oncol. 2008 Sep;110(3):408-17
18597838
J Clin Oncol. 2005 Jan 1;23(1):127-32
15625367
Annu Rev Pathol. 2009;4:287-313
18842102
J Clin Oncol. 2008 Sep 1;26(25):4160-5
18757330
Lancet Oncol. 2006 Mar;7(3):223-9
16510331
Mol Oncol. 2009 Apr;3(2):97-137
19383374
Int J Gynecol Pathol. 2008 Jan;27(1):1-9
18156967
Am J Surg Pathol. 1982 Mar;6(2):93-108
7102898
J Natl Cancer Inst. 1998 Nov 18;90(22):1729-34
9827528
Mol Oncol. 2009 Apr;3(2):165-70
19383378
Gynecol Oncol. 2008 May;109(2):168-73
18342932
Am J Surg Pathol. 1992 Jun;16(6):600-10
1599038
Am J Surg Pathol. 2001 Oct;25(10):1283-9
11688463
J Clin Oncol. 2007 Sep 1;25(25):3985-90
17761984
Clin Cancer Res. 2005 Sep 1;11(17):6116-26
16144910
N Engl J Med. 2002 May 23;346(21):1609-15
12023992
Int J Gynecol Pathol. 2009 Jul;28(4):308-15
19483636
Gynecol Oncol. 2009 Oct;115(1):108-111
19615727
Int J Gynecol Pathol. 2008 Apr;27(2):151-60
18317228